ArticleBipolar disorders2026
Psychotropic Prescribing Patterns Among Bipolar-I Patients Prior to Established Bipolar-I Disorder Diagnosis.
Article in Bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBipolar I Disorder (BP-I) is frequently misdiagnosed as Major Depressive Disorder (MDD), delaying appropriate treatment. This study aimed to examine treatment patterns among BP-I patients misdiagnosed with MDD and assess the impact of these regimens on the time until BP-I diagnosis.
methodsA retrospective cohort study was conducted using the MarketScan Commercial Claims and Encounters database, analyzing 21,771 BP-I patients initially misdiagnosed with MDD and 50,667 correctly diagnosed BP-I patients. Treatment patterns and their influence on time to BP-I diagnosis were assessed using multinomial logistic regression and Cox proportional hazards models.
resultsAmong the misdiagnosed cohort, 25.1% were initially started on antidepressant monotherapy, with 8.7% continuing this regimen after BP-I diagnosis. In contrast, 7.6% of the initially BP-I diagnosed cohort received antidepressant monotherapy. The time to BP-I conversion was shortest for those on mood stabilizer monotherapy (HR: 1.26, 95% CI: 1.19-1.34, p < 0.001), compared to those on antidepressant monotherapy. After BP-I diagnosis, patients originally misdiagnosed with MDD had different prescribing patterns, exhibiting lower rates of guideline-consistent treatments. Specifically, patients initially diagnosed with BP-I were more likely to receive mood stabilizing therapy, either as monotherapy (OR = 2.63, p < 0.001) or in combination with an antidepressant (OR = 1.84, p < 0.001).
conclusionMisdiagnosis of BP-I as MDD leads to significant delays in accurate diagnosis and inappropriate treatment regimens, highlighting the critical need for improved diagnostic accuracy at initial presentation. Prompt and accurate BP-I diagnosis can optimize treatment approaches and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.